BACKGROUND: The relationship between myocardial metabolic changes and the severity of left ventricular (LV) hypertrophy in patients with hypertrophic cardiomyopathy (HCM) is largely unknown. We characterized metabolic abnormalities in patients with a genetically identical cause for HCM but with variable LV hypertrophy. METHODS AND RESULTS: Eight patients with HCM attributable to the Asp175Asn mutation in the alpha-tropomyosin gene underwent myocardial perfusion, oxidative, and free fatty acid (FFA) metabolism measurements via positron emission tomography and oxygen 15-labeled water, carbon 11 acetate, and fluorine 14(R,S)-[18F] Fluoro-6-thia-heptadecanoic acid (18 FTHA). LV mass, work, and efficiency were assessed by echocardiography. Thirty-six healthy volunteers served as control subjects. Compared with control subjects, HCM patients had increased myocardial oxidative metabolism and FFA uptake (P < .05). However, in patients, LV mass was inversely related to global myocardial perfusion, oxidative metabolism, and FFA uptake (all P < .03), and regional wall thickness was inversely related to regional perfusion (P < .01), oxidative metabolism (P < .001), and FFA uptake (P < .01). Therefore patients with mild (LV mass less than median of 177 g) but not advanced LV hypertrophy were characterized by increased perfusion, oxidative metabolism, and LV efficiency as compared with control subjects (P < .05). CONCLUSIONS: In HCM attributable to the Asp175Asn mutation in the alpha-tropomyosin gene, myocardial oxidative metabolism and FFA metabolism are increased and inversely related to LV hypertrophy at both the whole heart and regional level. Increased metabolism and efficiency characterize patients with mild myocardial hypertrophy. These hypermetabolic alterations regress with advanced hypertrophy.
BACKGROUND: The relationship between myocardial metabolic changes and the severity of left ventricular (LV) hypertrophy in patients with hypertrophic cardiomyopathy (HCM) is largely unknown. We characterized metabolic abnormalities in patients with a genetically identical cause for HCM but with variable LV hypertrophy. METHODS AND RESULTS: Eight patients with HCM attributable to the Asp175Asn mutation in the alpha-tropomyosin gene underwent myocardial perfusion, oxidative, and free fatty acid (FFA) metabolism measurements via positron emission tomography and oxygen 15-labeled water, carbon 11 acetate, and fluorine 14(R,S)-[18F] Fluoro-6-thia-heptadecanoic acid (18 FTHA). LV mass, work, and efficiency were assessed by echocardiography. Thirty-six healthy volunteers served as control subjects. Compared with control subjects, HCM patients had increased myocardial oxidative metabolism and FFA uptake (P < .05). However, in patients, LV mass was inversely related to global myocardial perfusion, oxidative metabolism, and FFA uptake (all P < .03), and regional wall thickness was inversely related to regional perfusion (P < .01), oxidative metabolism (P < .001), and FFA uptake (P < .01). Therefore patients with mild (LV mass less than median of 177 g) but not advanced LV hypertrophy were characterized by increased perfusion, oxidative metabolism, and LV efficiency as compared with control subjects (P < .05). CONCLUSIONS: In HCM attributable to the Asp175Asn mutation in the alpha-tropomyosin gene, myocardial oxidative metabolism and FFA metabolism are increased and inversely related to LV hypertrophy at both the whole heart and regional level. Increased metabolism and efficiency characterize patients with mild myocardial hypertrophy. These hypermetabolic alterations regress with advanced hypertrophy.
Authors: H Laine; C Katoh; M Luotolahti; H Yki-Järvinen; I Kantola; A Jula; T O Takala; U Ruotsalainen; H Iida; M Haaparanta; P Nuutila; J Knuuti Journal: Circulation Date: 1999-12-14 Impact factor: 29.690
Authors: Hideshi Niimura; Kristen K Patton; William J McKenna; Johann Soults; Barry J Maron; J G Seidman; Christine E Seidman Journal: Circulation Date: 2002-01-29 Impact factor: 29.690
Authors: M Grover-McKay; M Schwaiger; J Krivokapich; J K Perloff; M E Phelps; H R Schelbert Journal: J Am Coll Cardiol Date: 1989-02 Impact factor: 24.094
Authors: A Hedman; J Hartikainen; E Vanninen; T Laitinen; P Jääskeläinen; M Laakso; K Peuhkurinen; J Kuusisto Journal: J Mol Cell Cardiol Date: 2004-01 Impact factor: 5.000
Authors: Jenifer G Crilley; Ernest A Boehm; Edward Blair; Bheeshma Rajagopalan; Andrew M Blamire; Peter Styles; William J McKenna; Ingegerd Ostman-Smith; Kieran Clarke; Hugh Watkins Journal: J Am Coll Cardiol Date: 2003-05-21 Impact factor: 24.094
Authors: Robert J Gropler; Rob S B Beanlands; Vasken Dilsizian; E Douglas Lewandowski; Flordeliza S Villanueva; Maria Cecilia Ziadi Journal: J Nucl Med Date: 2010-05-01 Impact factor: 10.057
Authors: Tetsuo Konno; Dan Chen; Libin Wang; Hiroko Wakimoto; Polakit Teekakirikul; Matthew Nayor; Masataka Kawana; Seda Eminaga; Joshua M Gorham; Kumar Pandya; Oliver Smithies; Francisco J Naya; Eric N Olson; J G Seidman; Christine E Seidman Journal: Proc Natl Acad Sci U S A Date: 2010-10-05 Impact factor: 11.205
Authors: Stefan A J Timmer; Tjeerd Germans; Marco J W Götte; Iris K Rüssel; Pieter A Dijkmans; Mark Lubberink; Jurrien M ten Berg; Folkert J ten Cate; Adriaan A Lammertsma; Paul Knaapen; Albert C van Rossum Journal: Eur J Nucl Med Mol Imaging Date: 2010-01-13 Impact factor: 9.236
Authors: Donna K Arnett; Ramachandran S Vasan; Matthew Nayor; Li Shen; Gary M Hunninghake; Peter Kochunov; R Graham Barr; David A Bluemke; Ulrich Broeckel; Peter Caravan; Susan Cheng; Paul S de Vries; Udo Hoffmann; Márton Kolossváry; Huiqing Li; James Luo; Elizabeth M McNally; George Thanassoulis Journal: Circ Cardiovasc Imaging Date: 2021-08-13 Impact factor: 8.589
Authors: Benedicte Jørgenrud; Mikko Jalanko; Tiina Heliö; Pertti Jääskeläinen; Mika Laine; Mika Hilvo; Markku S Nieminen; Markku Laakso; Tuulia Hyötyläinen; Matej Orešič; Johanna Kuusisto Journal: PLoS One Date: 2015-08-12 Impact factor: 3.240